Trusted Resources: News & Meetings
Latest announcements and gatherings
Regenxbio Presents Positive Initial Data From Phase I/II Trial Of Rgx-111 for the Treatment of Severe MPS I at 18th Annual World Symposium™ 2022
REGENXBIO Inc. (Nasdaq: RGNX) today announced positive interim data are being presented at the 18th Annual WORLDSymposium™ from five patients in the ongoing Phase I/II trial and one patient from a single-patient Investigational New Drug (IND) application of RGX-111 for the treatment of severe Mucopolysaccharidosis Type I (MPS I).
RGX-111 is an investigational one-time gene therapy designed to deliver the gene that encodes the IDUA enzyme using the AAV9 vector. RGX-111 is administered directly to the CNS. The primary endpoint of the trial is to evaluate the safety of RGX-111. Secondary and exploratory endpoints include biomarkers of α-l-iduronidase (IDUA) enzyme activity in the cerebrospinal fluid (CSF), serum and urine, neurodevelopmental assessments, and caregiver reported outcomes.
BookmarkRelated Content
-
Intracerebral Gene Therapy in Four Children With Sanfilippo B Syndrome: 5.5-Year Follow-Up ResultsWe report the safety (primary endpoint) ...
-
Expanding the Phenotype of Mucopolysaccharidosis Type II RetinopathyPurpose: To report novel retinal finding...
-
The Beginning of the End of Allogeneic Transplantation for Hurler SyndromeHurler syndrome (mucopolysaccharidosis t...
-
Mucopolysaccharidoses Type I Gene TherapyMucopolysaccharidoses type I (MPS I) is ...
-
Paul Orchard, MDDr. Paul Orchard is the Medical Director...
-
Fetal Therapies and Trials for Lysosomal Storage Diseases: A Survey of Attitudes of Parents and PatientsLysosomal storage diseases (LSDs) are in...
-
Sanfilippo Ideal for FDA’s Accelerated Approval Pathway, Foundation SaysThe Cure Sanfilippo Foundation is encour...
Powered by
